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ABSTRACT
Late onset multiple sclerosis (LOMS) is when the first symptom starts after 50 years of age, representing 4.5% of multiple sclerosis (MS) 
patients. This study describes the clinical characteristics of patients with LOMS followed at a specialized MS center in São Paulo. Data 
was obtained from medical records of 742 patients with MS. The LOMS frequency was 4.18%, median age at onset was 54 years and the 
predominant disease course was primary progressive (64.3%). The patients reached the disability landmarks of EDSS grades 3.0, 6.0 and 
7.0 in the following proportion and time: EDSS 3.0: 77.42% of patients in 3.7 years; EDSS 6.0: 58.06% in 5.1 years and EDSS 7.0: 32.26% in 
5.7 years. The comparative analysis with a matched control group of patients with early onset MS showed that late onset, associated with a 
progressive course, were predictors of reaching EDSS 3.0 and 6.0 in a shorter time. 
Keywords: aging; epidemiology; multiple sclerosis; disease progression.
RESUMO
Esclerose múltipla de inicio tardio (EMIT) caracteriza-se pelo início de sintomas aos 50 ou mais anos de idade, representando 4,5% dos 
pacientes com esclerose múltipla (EM). Este estudo descreve as características clínicas de pacientes com EMIT acompanhados num centro 
de EM em São Paulo. Dados foram obtidos através de análise de prontuário de 742 pacientes com EM. A frequência de EMIT foi de 4,18%, 
a mediana da idade de início foi de 54 anos e a forma clínica predominante a primariamente progressiva (64,3%). Os pacientes atingiram os 
marcos de incapacidade EDSS 3, 6 e 7 nas respectivas proporções e tempo: EDSS 3.0, 77,42% de pacientes em 3.7 anos; EDSS 6.0, 58,06% 
em 5.1 anos e EDSS 7.0, 32,26% em 5.7 anos. A análise comparativa a um grupo controle de jovens com EM, mostrou que o início tardio 
associado a forma primariamente progressiva foram preditores para atingir EDSS 3 e 6 num período menor. 
Palavras-chave: envelhecimento; epidemiologia; esclerose múltipla; progressão da doença.
Multiple sclerosis (MS) is an inflammatory autoim-
mune disease of the central nervous system that predomi-
nantly affects young adults between 20 and 40 years of age. 
Therefore, an uncommon form of MS is one in which symp-
toms start at 50 plus years of age, called late onset multiple 
sclerosis (LOMS)1,2,3,4,5,6,7,8. It accounts for 1.4% to 9.9% of the 
MS population in different countries2,4,5,7,9,10,11,12.
On average, LOMS represents roughly 4.5% of the MS popu-
lation2,4,5,7, it has a female preponderance1,2,4,7,12, its initial presenta-
tion is monosymptomatic, with a motor or cerebellar symptom, 
and the most common clinical course is primary progressive4,13,14. 
The progression to disability in LOMS has previously been 
attributed to disease duration time15, to clinical form2, gender8, 
and older age at the time of the patient’s first examination13. 
The later onset has been associated with a greater possibility 
of reaching Expanded Disability Status Scale (EDSS) grade 6.0 
in a shorter period16. 
Vascular disease of the central nervous system and cervi-
cal spondylotic myelopathy are the main differential diagno-
ses, due to a higher prevalence at this age and possible similar 
symptoms1,4,13,17,18. Because of previous co-morbid conditions 
and higher odds of T2-hyperintense lesions on magnetic reso-
nance imaging (MRI) of elderly patients7,13,19, there is a delay in 
diagnosis that can reach three to five years in almost 40% of 
LOMS patients7,14,20.
There is scanty literature concerning what influences the 
presentation and progression to disability in this age group, 
and few papers compare this population with young MS adults. 
The purpose of this study is to describe the demographic, 
clinical and laboratory characteristics of patients with LOMS 
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followed at the MS center of the Neurology Department of 
the Federal University of São Paulo.
METHODS
The Neuroimmunology Clinic of the Federal University of 
São Paulo is a specialized center for the treatment of patients 
with MS and other demyelinating diseases. It has maintained a 
database with information on clinical status, laboratory tests, 
radiological evaluation and treatment of all patients under fol-
low up, since 1994. Data for this retrospective cohort study was 
obtained from the medical records of 742 patients with MS. 
The LOMS patients were defined by the occurrence of the 
first MS symptoms after age 50, meeting either Poser’s or the 
McDonald criteria, depending on the current diagnostic cri-
teria at the moment of their first appointment. According to 
the current diagnostic criteria, neuromyelitis optica patients 
were excluded from the analysis.
Information gathered from their clinical records included: 
demographic characteristics; disease onset and duration; fol-
low-up time; onset, first and last visit symptoms and signs; 
EDSS scores in the first and last visit; disease course; number 
of relapses, progression index; MRI data, cerebral spinal fluid 
(CSF) and evoked potential findings.
Additionally, LOMS patients were compared to a young 
onset MS (YOMS) control group, matched according to sex and 
clinical form, in a 2:1 proportion. For this analysis, nine LOMS 
patients with a follow-up of less than 12 months were excluded.
This study was approved by the local institutional ethics 
committee  (IRB) and registered under number 256958. 
Statistical analyses
Continuous variables were tested for normality with the 
Kolmogorov-Smirnov and Shapiro Wilk tests and the values 
are expressed as median and percentiles 25 and 75. The cat-
egorical data are presented as absolute values and percent-
ages and were tested using Pearson’s χ2 test and Fisher’s 
exact test, if applicable. 
Nonparametric data was compared using the Mann-Whitney 
U test for two independent samples. 
Discrimination of variables was calculated by a receiver 
operator characteristic curve (ROC curve) utilizing the area 
under the curve and asymptotic significance. Some con-
tinuous variables were categorized through the ROC curve. 
The cutoff points were calculated using the value with the 
best sensitivity and specificity. 
The Kaplan-Meier model with log-rank test was applied 
at times, to obtain EDSS values.
A cox proportional model was used to determine predic-
tive factors for reaching specific EDSS milestones and the 
hazards ratios were calculated.
Statistical significance was considered with p ≤ 0.05 and 
the analyses were performed using SPSS 19.0.
RESULTS
LOMS population
Of the 742 patients with MS, 31 were LOMS patients, rep-
resenting a percentage of 4.18%. The gender distribution was 
2.1 females to 1 male patient, of whom 19 were Caucasian, 
three were Afro-descendant, two were of mixed ethnicity and 
there was no information on seven patients. The median age 
of initial symptoms was 54, 22 patients (71%) were between 
50 and 55 years old, and only two patients were over 60 years 
old, which is referred to as very late onset MS. 
The initial neurological presentation was motor impair-
ment in 54.8% and cerebellar involvement in 29.0%, sensory 
impairment and brainstem symptoms in 19.4% each, visual 
in 16.1% and vesical dysfunction in 3.2% A multi-topographic 
involvement was described in 38.7%, and the most frequent 
combination was motor and cerebellar.
Three patients did not have enough information to define 
their clinical course, therefore they were excluded from the 
LOMS population analysis. Of the remaining 28 patients, 64.3% 
were primary progressive and 35.7% relapsing-remitting. In our 
study, there were no secondary progressive cases of LOMS. 
The median follow-up period was 2.2 years and 3.1 years 
for primary progressive multiple sclerosis (PPMS) and relaps-
ing-remitting multiple sclerosis (RRMS), respectively, while 
median disease time was of 9.2 for PPMS and 4.9 years for 
RRMS. Considering the RRMS patients, 70% had their second 
relapse less than a year after the first symptom. The median 
EDSS scores on the first and last evaluation for the RRMS 
group was 2.0 on both visits, and for the PPMS group was 2.0 
at the initial visit and 7.0 on the last visit. Patients with LOMS 
reached the disability landmarks of EDSS 3.0, 6.0 and 7.0 in the 
following proportion and time: EDSS 3.0: 77.42% of patients in 
3.7 years; EDSS 6.0: 58.06% in 5.1 years, and EDSS 7.0: 32.26% 
in 5.7 years (Tables 1 and 2). Of the 31 patients, three deaths 
Table 1. Demographic and clinical data of the late onset 
multiple sclerosis patients with well-defined disease course.
Clinical course
RRMS PPMS
n  (%) n  (%)
Gender        
Female 7 70.0 11 61.1
Male 3 30.0 7 38.9
Ethnicity        
Caucasian 5 71.4 12 80.0
African descendent 1 14.3 2 13.3
Mixed ethnicity 1 14.3 1 6.7
  Median (25–75) Median (25–75)
Time        
Age of onset 54 (52–54) 54 (51–57) 
Disease duration (years) 4.9 (4.0–7.9) 9.2 (3.3–11.6)
Follow-up time (months) 37.5 (21.8–56.7) 25.8 (12.1–76.1)
Time to reach EDSS 3 (years) 3.8 (1.4–7.3) 3.8 (1.0–4.1)
RRMS: relapsing remitting multiple sclerosis; PPMS: primary progressive 
multiple sclerosis; n: number of patients; EDSS: expanded disability status scale. 
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occurred during the follow-up: one from gastrointestinal 
bleeding, one myocardial infarction and one unknown cause. 
Descriptions of brain MRI scans were compatible with 
MS in all patients. Sixteen of them had descriptions of spinal 
cord MRIs, of which nine (56.3%) had one or more lesions. 
Only 11 patients had their CSF analyzed, of which 54.5% had 
oligoclonal bands. Only six had visual evoked potential stud-
ies, with altered potentials in five (83.3%).
LOMS versus YOMS
Twenty-two LOMS patients were compared to 44 patients 
with YOMS, whose initial symptom had started between 20 
and 40 years of age. 
We found no significant statistical difference between 
initial symptoms or functional system reported by either 
group on initial or final evaluation. The predominant ini-
tial symptom in RRMS patients was brainstem in the LOMS 
(44%) and sensitive in the YOMS (39%), while patients with 
the progressive form in both groups had predominantly 
motor symptoms. 
The progression index (calculated by dividing the EDSS 
score by the disease duration time) was worse in the LOMS 
patients, more clearly seen in the PPMS group, 0.55 versus 
0.74, for younger and older onset respectively. The annual 
relapsing rate was higher in the younger group (median of 0.7 
versus 0.51). Neither of these differences had statistical sig-
nificance (Tables 3 and 4).
Table 4. Young onset primary progressive multiple sclerosis group comparison to the late onset primary progressive multiple 
sclerosis group.
PPMS (Age onset)
< 50 YOPPMS ≥ 50 LOPPMS Mann-Whitney
Median (25% - 75%) Median (25% - 75%) p-value
Disease Duration (years) 13.5 (8.7–16.5) 7.2 (3.3–11.6) 0.021
Follow up (months) 86.1 (67–124.1) 25.8 (16.1–76.1) 0.005
EDSS-First Visit+ 3.5 (3.0–6.0) 3.0 (3.0–4.0) 0.219
EDSS-Last Visit++ 6.5 (6.5–8.0) 7.5 (6.5–8.0) 0.691
Time from onset to initial evaluation (months) 49.3 (30.3–73.6) 49.0 (27.7–49.6) 0.452
PI (Progression Index) 0.55 (0.43–0.81) 0.74 (0.63–1.83) 0.058
Time to reach EDSS 3 (years) 3.0 (2.1–4.1) 3.1 (0.9–4.1) 0.711
Time to reach EDSS 6 (years) 6.8 (4.6–10.5) 5.5 (2.8–8.7) 0.324
Time to reach EDSS 7 (years) 9.0 (8–14.3) 7.3 (4.3–11.6) 0.168
PPMS: primary progressive multiple sclerosis; YOPPMS: young onset primary progressive multiple sclerosis; LOPPMS: late onset primary progressive multiple 
sclerosis; EDSS: expanded disability status scale; n: number of patients.
Table 2. EDSS milestones of the 31 late onset multiple 
sclerosis patients, despite disease course.
Variable Median (25%–75%)
First visit EDSS 3 (2.5– 6.0)
Last visit EDSS 6.5 (2.5–8.0)
Time in years to EDSS 3 3.7 (0.7– 5.9)
Time in years to EDSS 6 5.1 (2.9–8.7)
Time in years to EDSS 7 5.7 (3.5–10.5)
  n %
Reached EDSS 3 24 77.40
Reached EDSS 6 18 58.1 
Reached EDSS 7 10 32.30
EDSS: expanded disability status scale; n: number of patients.
Table 3. Young onset relapsing-remitting multiple sclerosis group comparison to the late onset relapsing-remitting multiple 
sclerosis group.
RRMS (age onset)
< 50 YORRMS ≥ 50 LORRMS Mann-Whitney
Median (25%–75%) Median (25%–75%) p-value
Disease duration (years) 5.6 (3.4–9.5) 5.4 (4.2–7.9) 0.980
Follow up (months) 36.7 (23.7–68.1) 44.1 (28.3–56.7) 0.940
EDSS-First Visit+ 2.0 (1.0–2.5) 2.0 (1.5–3.5) 0.668
EDSS-Last Visit++ 2.0 (1.0–2.0) 2.5 (2.0–3.0) 0.176
Total number of relapses 3.0 (3.0–5.0) 3.0 (2.0–4.0) 0.298
Time in months from 10 to 20 relapse 11.1 (6.1–25.4) 8.1 (2.0–22.3) 0.322
Time from onset to initial evaluation (months) 12.2 (7.6–49.5) 15.1 (6.9–37.7) 0.980
Annual relapse rate 0.7 (0.34–1.05) 0.51 (0.48–0.68) 0.253
Progression Index 0.3 (0.25–0.34) 0.4 (0.23–0.54) 0.616
Time to reach EDSS 3 (years) 4.6 (2.7 -7.0) 3.8 (1.4–7.3) 0.628
Time to reach EDSS 6 (years) 5.6 (2.9–9.5) 5.4 (4.2–8.7) 0.999
Time to reach EDSS 7 (years) 5.6 (3.4–9.5) 5.4 (4.2–8.7) 0.999
RRMS: relapsing-remitting multiple sclerosis; YORRMS: Young onset relapsing-remitting multiple sclerosis; LORRMS: late onset relapsing-remitting multiple 
sclerosis; EDSS: expanded disability status scale.
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The median time to reach EDSS 3.0, 6.0 and 7.0 for the 
older RRMS patients was 3.8, 5.4 and 5.4 years, respectively, 
and in the younger group was 4.6, 5.6 and 5.6 years. In the 
PPMS group, the older patients reached EDSS grades 3.0, 
6.0 and 7.0 in 3.1, 5.5 and 7.3 years, while the young patients 
reached these landmarks in 3.0, 6.8 and 9.0 years, respectively 
(Figure). The three EDSS milestones were reached in less 
time in the LOMS group compared to the YOMS, but there 
was no statistical significance (Tables 3 and 4).
The cox regression models were applied to find the pre-
dictive factors for reaching the EDSS grades 3.0 and 6.0 in a 
shorter time. We observed that patients who were 50 years 
and older and the ones with a primary progressive form, 
reached EDSS grades 3.0 and 6.0 significantly earlier. These 
variables were co-dependent (Table 5).
All patients had brain MRI scans that fulfilled dissemina-
tion in time and space, compatible with an MS diagnosis at first 
visit. Spinal MRI was performed in four patients with late onset 
RRMS, but did not show any spinal cord abnormalities, in con-
trast to the young group, in which 90% of the scans showed MS 
lesions. Conversely, within the PPMS patients, spinal inflamma-
tory lesions were found in both age groups at the same propor-
tion. We observed that the positivity of oligoclonal bands in spi-
nal fluid was much higher in the younger group (Table 6). 
DISCUSSION
The population of Brazilian LOMS patients described 
in this retrospective cohort seems to be very similar to 
previously-published LOMS descriptions. We observed the same 
frequency of 4.18%, among patients with MS2,3,4,5,7; a female pre-
dominance of 2.1:11,2,4,7,12,14, a Caucasian preponderance12; a similar 
age of onset2,4,7,11,14 and a higher percentage of the primary progres-
sive form, that reached up to 83% in some descriptions1,2,4,7,9,11,14,17,21.
Interestingly, very late onset MS (defined as the first symp-
tom at 60 years or above), represented 0.27% of our cohort. This 
figure is lower when compared to other series, which reported a 
prevalence of 0.45% to 1.33%2,3,5,9,12,17. A possible explanation for 
this finding is the fact that Brazilians may die of other causes 
before a diagnosis of MS can be made, or since MS is not a com-
mon disease in Brazil, the correct diagnosis might be delayed or 
never made. The few papers that report this age range, empha-
size that they have the same clinical characteristics of LOMS 
patients, but with a larger delay in diagnosis17,22,23. In the future 
with the aging world population and easier access to MRIs, very 
late onset MS may be more frequently described24.
Concerning disease duration, late onset PPMS had a 
median duration time twice as long as late onset RRMS. 
Conversely, when it comes to follow-up time, the oppo-
site occurs – late onset RRMS patients have a slightly lon-
ger follow-up history (3.13 versus 2.15 years). This could be 
explained by the longer time it usually takes to diagnose 
the progressive form, with a clear delay from initial symp-
tom to first appointment at the MS clinic (4.12 years versus 
1.15 years with the RRMS patients), as seen in Tables 4 and 
5. The delay in diagnosis of the primary progressive form of 
LOMS has been observed by other authors, and may be justi-
fied by the fact that other diseases such as vascular disease of 
the central nervous system and cervical spondylotic myelop-
athy have a higher prevalence at this age and may present 
with similar symptoms7,13,14. Our short follow-up time may be 
due to the delay in patients being referred to a specialized MS 
center, and because of abandonment of the follow-up. 
Similar to previously-described series, we observed a higher 
frequency of motor and cerebellar symptoms2,9,11,12,13,14,25,26 and 
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Highlights: 1) This is the first Latin American study of demographic and clinical characteristics of patients with Late Onset Multiple Sclerosis (LOMS) followed at a 
specialized multiple sclerosis (MS) center in São Paulo; 2) LOMS frequency was 4,18% of all multiple sclerosis patients; 3)Comparative analysis with a matched control 
group of patients with young onset MS showed that the late onset associated with a progressive course were predictors of reaching EDSS 3.0 and 6.0 in a shorter time.
Figure. Kaplan-Meier estimates of time to reach EDSS 3 and 6 in LOMS and YOMS patients.
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a high percentage of initial multifocal involvement4,7 espe-
cially compared to young adults with MS10. A possible expla-
nation is an association of the primary progressive form with 
a multifocal presentation. Such an hypothesis is corrobo-
rated by a study performed exclusively with late onset RRMS 
patients that reported a multifocal presentation in only 11% 
of patients25.
In our cohort, we observed that 70% of the patients with 
late onset RRMS had the second relapse in less than a year, 
in spite of presenting with a low annual relapse rate. Different 
studies reported a similar low annual relapse rate in the late 
onset RRMS group, compared to the young onset RRMS 
group, in spite of a shorter interval between the first and sec-
ond relapse. This low annual relapse rate in older patients 
could be attributed to a more inflammatory disease in young 
patients1,3,12,18,23,27,28. Recovery after the first relapse is better in 
younger patients and the chances of full recovery after a relapse 
decreases by 1% for each year older the patient is at onset9,25. 
This could explain why late onset RRMS patients acquire sus-
tained severe neurological disability in a short period of time.
Regarding disability, 25.8% of LOMS patient were 
already at EDSS 6.0 at their first appointment at the MS 
clinic, and on final examination, the progressive form 
showed worse outcomes, concurring with previous series 
(Tables 4 and 5)2,20,27,29. In RRMS, the median time for LOMS 
patients to reach EDSS 3.0, 6.0 and 7.0 was almost identical 
to the younger group. On the other hand, for PPMS, the time 
to reach EDSS 6.0 and 7.0 was longer for the young group 
compared to LOMS, and the progression index diverged 
between LOMS and the younger group, 0.74 and 0.55, 
respectively, as seen in other studies4,11,14,17,27. These findings 
had no statistical significance, probably due to our small 
sample. We were able to significantly demonstrate that the 
late disease onset, as well as the primary progressive form, 
are predicting factors for reaching EDSS 3.0 and 6.0 in a 
shorter time, as two co-dependent variables, and similar to 
studies published1,2,11,12,18,27,29. Reaching disability milestones 
in a shorter period does not infer worse prognosis, consid-
ering that LOMS reached these at ages five to 11 years later 
than the young adults2,18. Some authors state that disability 
is influenced by the age at which the patient was first eval-
uated, thus patients older than 50 years, tend to have the 
same disabilities, regardless of the age of disease onset13,15,28. 
In our LOMS population, oligoclonal bands proved not to 
assist in the MS diagnosis. Only five out of the 10 LOMS patients 
were oligoclonal band positive. This lower percentage com-
pared to previous series1,7,14,17,18 is possibly due to differences 
in laboratory techniques or to the disease period in which the 
test was done. However, our finding is in agreement with the 
hypothesis that older patients have lower levels of inflamma-
tory and neurodegenerative biomarkers in their CSF30. Spinal 
MRI seems to be an important additional diagnostic tool in 
LOMS patients who usually show signs of microangiopathy 
on brain MRI. We observed that 50% of the 12 LOMS patients 
submitted to spinal MRI had lesions, thus helping to differenti-
ate between MS and vascular diseases11,14,18. Our study demon-
strated that spinal MRI may be a helpful diagnostic tool only in 
the primary progressive LOMS group, in which we found 75% 
of clusters with lesions shown in spinal MRI, a high percentage, 
as expected in this clinical course6,11,18.
Clearly, there are limitations to our study. It is a descrip-
tion of a small population based on a retrospective review of 
medical records. It covers 20 years and the changes in diag-
nostic criteria may have introduced a bias in the comparison 
of the different groups of patients. Nonetheless, it is the first 
Latin America description of a LOMS population and we dem-
onstrated its similarities to other cohorts previously described. 
The LOMS patients represent almost 5% of the MS population, 
and it is important to better understand its characteristics, 
pattern of disability progression and disease-modifying factors, 
such as treatment. Further studies are warranted, especially to 
determine how age influences the clinical course, treatment 
response and permanent neurological disability.
Table 5. Cox proportion regression to find the predictive 
factors for reaching the EDSS 3 and 6 in a shorter time.
Variables of the 
equation* p-value
Hazard 
Ratio
Confidence interval
95% Low 95% High
EDSS 3.0
Clinical course < 0.0001 3.923 2.003 7.683
Age of onset < 0.0001 0.083 0.020 0.345
EDSS 6.0
Clinical course < 0.0001 6.687 2.365 18.909
Age of onset 0.002 0.036 0.004 0.308
*Variables adjusted by Gender; EDSS: expanded disability status scale. 
Table 6. Spinal fluid analysis for the presence of oligoclonal bands in both disease courses, and the description of altered 
(presence of one or more lesions) or normal spinal MRI in both disease courses.
Variable Age of onset
< 50 ≥ 50 Pearson Qui-Square
n (N) % n (N) % p-value
OCB in RRMS Presence 5 (9) 56 3 (4) 75 0.506
Spinal MRI in RRMS Altered 9(10) 90 0 (4) 0 0.001
OCB in PPMS Presence 4 (4) 100 2 (6) 33 0.035
Spinal MRI in PPMS Altered 6 (8) 75 6 (8) 75 0.999
N: total of patients submitted to the exam described in the first column; n: number of patients with alteration of the exam; OCB: Oligoclonal bands; MRI: Magnetic 
resonance imaging; RRMS: relapsing-remitting multiple sclerosis; PPMS: primary progressive multiple sclerosis.
456 Arq Neuropsiquiatr 2017;75(7):451-456
References
1. Noseworthy JH, Paty D, Wonnacott T, Feasby T, Ebers G. Multiple 
sclerosis after age 50. Neurology, 1983;33912):1537-44. 
https://doi.org/10.1212/WNL.33.12.1537
2. Tremlett H, Devonshire V. Is late-onset multiple sclerosis 
associated with a worse outcome? Neurology. 2006;67(6):954-9. 
https://doi.org/10.1212/01.wnl.0000237475.01655.9d
3. White AD, Swingler RJ, Compston DAS. Features of multiple sclerosis 
in older patients in South Wales. Gerontology. 1990;36(3):159-64. 
https://doi.org/10.1159/000213192
4. Polliack ML, Barak Y, Achiron A. Late-onset multiple sclerosis. J Am Geriatr 
Soc. 2001;49(2):168-71. https://doi.org/10.1046/j.1532-5415.2001.49038.x
5. Delalande S, De Seze J, Ferriby D, Stojkovic T, Vermersch P.  [Late onset 
multiple sclerosis]. Rev Neurol (Paris). 2002;158(11):1082-7. French.
6. Seze J, Delalande S, Michelin E, Gauvrit JY, Mackowiak MA, 
Ferriby D et al. Brain MRI in late-onset multiple sclerosis. Eur J Neurol. 
2005;12(4):241-4. https://doi.org/10.1111/j.1468-1331.2004.01103.x
7. Arias M, Dapena D, Arias-Rivas S, Costa E, López A, Prieto JM et al. 
Late onset multiple sclerosis. Neurologia. 2011;26(5):291-6. 
https://doi.org/10.1016/j.nrl.2010.09.008
8. Bove R, Musallam A, Healy BC, Houtchens M, Glanz BI, Khoury S et al. 
No sex-specific difference in disease trajectory in multiple sclerosis 
patients before and after age 50. BCM Neurology. 2013;13(73):73. 
https://doi.org/10.1186/1471-2377-13-73
9. Leibowitz U, Alter M, Halpern L. Clinical studies of multiple sclerosis 
in Israel. III. Clinical course and prognosis related to age at onset. 
Neurology. 1964;14(10):926-32. https://doi.org/10.1212/WNL.14.10.926
10. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and 
progression of irreversible disability in multiple sclerosis: an amnesic 
process. Brain. 2003;126(4):770-82. https://doi.org/10.1093/brain/awg081
11. Etemadifar M, Abtahi SH, Minagar A, Akbari M, Masaeli A, 
Tabrizi N. Late-onset multiple sclerosis in Isfahan, Iran. Arch Iran 
Med. 2012;15(10):596-8.
12. Bove RM, Healy B, Augustine A, Musallam A, Gholipour T, 
Chitnis T. Effect of gender on late-onset multiple sclerosis. Mult Scler. 
2012;18(10):1472-9. https://doi.org/10.1177/1352458512438236
13. Martinelli V, Rodegher M, Moiola L, Comi G. Late onset multiple 
sclerosis: clinical characteristics, prognostic factors and differential 
diagnosis. Neurol Sci. 2004;25(Suppl 4):S350-55.3.
14. Kis B, Rumberg B, Berlit P. Clinical characteristics of patients with 
late-onset multiple sclerosis. J Neurol, 2008;255(5):697-702. 
https://doi.org/10.1007/s00415-008-0778-x
15. Liguori M, Marrosu MG, Pugliatti M, Giuliani F, De Robertis F, 
Cocco E et al. Age at onset in multiple sclerosis. Neurol Sci. 
2000;21(4 Suppl 2):S825-9. https://doi.org/10.1007/s100720070020
16. Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA. Age 
and disability accumulation in multiple sclerosis. Neurology. 
2011;77(13):1246-52. https://doi.org/10.1212/WNL.0b013e318230a17d
17. Hooge JP, Redekop WK. Multiple sclerosis with very late onset. Neurology. 
1992;42(10):1907-10. https://doi.org/10.1212/WNL.42.10.1907
18. Harding K, Griffiths M, Wardle M, Tomassini V, Pickersgill T, Robertson N. 
Late-onset multiple sclerosis in south-east wales. J Neurol Neurosurg 
Psychiatry. 2013;84(11). https://doi.org/10.1136/jnnp-2013-306573.26
19. Awad A, Stüve O. Multple sclerosis in the elderly patient. Drugs Aging. 
2010;27(4):283-94. https://doi.org/10.2165/11532120-000000000-00000
20. Harding K, Loveless S, Wardle M, Tomassini V, Pickers T, Robertson N. 
Epistatic effects on the phenotype of multiple sclerosis. J Neurol Neurosurg 
Psychiatry. 2013;84(11). http://dx.doi.org/10.1136/jnnp-2013-306573.30
21. Lyon-Caen O, Izquierdo G, Marteau R, Lhermitte F, 
Castaigne P, Hauw JJ. Late onset multiple sclerosis: a clinical study of 
16 pathologically proven cases. Acta Neurol Scand. 1985;72(1):56-60. 
https://doi.org/10.1111/j.1600-0404.1985.tb01547.x
22. Marra TR. Multiple sclerosis with onset after age 60. J Am Geriatr Soc. 
1984;32(1):16-8. https://doi.org/10.1111/j.1532-5415.1984.tb05144.x
23. Azzimondi G, Stracciari A, Rinaldi R, D’Alessandro R, 
Pazzaglia P. Multiple sclerosis with very late onset: report of six 
cases and review of the literature. Eur Neurol. 1994;34(6):332-6. 
https://doi.org/10.1159/000117073
24. Takeuchi T, Ogura M, Sato M, Kawai N, Tanihata H, 
Takasaka I et al. Late-onset tumefactive multiple sclerosis. Radiat 
Med. 2008;26(9):549-52. https://doi.org/10.1007/s11604-008-0273-4
25. Cossburn M, Ingram G, Hirst C, Ben-Shlomo Y, Pickersgill TP, 
Robertson NP. Age at onset as a determinant of presenting 
phenotype and initial relapse recovery in multiple sclerosis. Mult 
Scler. 2012;18(1):45-54. https://doi.org/10.1177/1352458511417479
26. Amador-Patarroyo MJ, Rodriguez-Rodriguez A, 
Montoya-Ortiz G. How does age at onset influence the outcome 
of autoimmune diseases? Autoimmune Dis. 2012;2012:251730. 
https://doi.org/10.1155/2012/251730
27. Poser S, Raun NE, Poser W. Age at onset, initial 
symptomatology and the course of multiple 
sclerosis. Acta Neurol Scand. 1982;66(3):355-62. 
https://doi.org/10.1111/j.1600-0404.1982.tb06856.x
28. Trojano M, Liguori M, Bosco Zimatore G, Bugarini R, Avolio C, 
Paolicelli D et al. Age-related disability in multiple sclerosis. 
Ann Neurol. 2002;51(4):475-80. https://doi.org/10.1002/ana.10147
29. Cottrell DA, Kremenchutzky M, Rice GPA, et al. The natural History 
of multiple sclerosis: 5. The clinical features and natural history 
of primary progressive multiple sclerosis. Brain. 1999;122:625-39. 
https://doi.org/10.1093/brain/122.4.625
30. Khademi M, Dring AM, Gilthorpe JD, Wuolikainen A, 
Al Nimer F, Harris RA et al. Intense inflammation and nerve damage 
in early multiple sclerosis subsides at older age: a reflection by 
cerebrospinal fluid biomarkers. PLoS One. 2013;8(5):e63172. 
https://doi.org/10.1371/journal.pone.0063172
